OyaGen, Inc. Developing Compound with Broad Antiviral Activity Against Coronaviruses
By HospiMedica International staff writers Posted on 24 Mar 2020 |
Image: hA3G in 293T cells (Photo courtesy of OyaGen, Inc.)
OyaGen, Inc.’s (Rochester, NY, USA) collaborative research with the National Institute of Allergy and Infectious Diseases (Fort Detrick, MD, USA) has suggested strong dose-dependent antiviral activity of its lead compound OYA1 against live SARS-CoV-2, the causative agent for COVID-19, based on in cell culture infectivity studies.
OyaGen is focused on the identification and early development of novel therapeutics for the treatment of viral diseases including HIV, coronavirus and Ebola. OYA1 has broad-spectrum antiviral activity in laboratory-based assays against the coronaviruses SARS-CoV-2 and MERS-CoV and also is a dual target-specific antiviral against filoviruses such as Ebola virus. OYA1 was strongly more effective than a positive-control compound, chlorpromazine HCl, at inhibiting SARS-CoV-2 from replicating in cell culture.
OYA1 had prior FDA approval as an investigational new drug for treating cancer in the 1960s but was abandoned for a lack of efficacy. Studies at that time demonstrated safety in non-human primates and human adults when dosed daily or weekly. Side effects can include cardiac toxicity in children when dosed every day. Side effects may be due to the slow metabolic turnover of OYA1 as demonstrated in earlier studies in mice, which suggested the compound may persist in tissues for greater than 12 days following a single dose, especially in heart tissue where cell turnover is low. However, its long half-life in tissues suggests that a single dose or weekly dosing may be sufficient for antiviral treatments.
OyaGen will conduct further studies for the safety and efficacy of OYA1 in treating COVID-19 as necessary for regulatory approval. The company anticipates that inhibition of SARS-CoV-2 using OYA1 will serve as a stop-gap treatment until appropriate vaccines are developed. OYA1 could also prove timely in addressing the need for combination therapy for SARS-CoV-2 to avoid the emergence of drug-resistant virus.
Related Links:
OyaGen, Inc.
National Institute of Allergy and Infectious Diseases
OyaGen is focused on the identification and early development of novel therapeutics for the treatment of viral diseases including HIV, coronavirus and Ebola. OYA1 has broad-spectrum antiviral activity in laboratory-based assays against the coronaviruses SARS-CoV-2 and MERS-CoV and also is a dual target-specific antiviral against filoviruses such as Ebola virus. OYA1 was strongly more effective than a positive-control compound, chlorpromazine HCl, at inhibiting SARS-CoV-2 from replicating in cell culture.
OYA1 had prior FDA approval as an investigational new drug for treating cancer in the 1960s but was abandoned for a lack of efficacy. Studies at that time demonstrated safety in non-human primates and human adults when dosed daily or weekly. Side effects can include cardiac toxicity in children when dosed every day. Side effects may be due to the slow metabolic turnover of OYA1 as demonstrated in earlier studies in mice, which suggested the compound may persist in tissues for greater than 12 days following a single dose, especially in heart tissue where cell turnover is low. However, its long half-life in tissues suggests that a single dose or weekly dosing may be sufficient for antiviral treatments.
OyaGen will conduct further studies for the safety and efficacy of OYA1 in treating COVID-19 as necessary for regulatory approval. The company anticipates that inhibition of SARS-CoV-2 using OYA1 will serve as a stop-gap treatment until appropriate vaccines are developed. OYA1 could also prove timely in addressing the need for combination therapy for SARS-CoV-2 to avoid the emergence of drug-resistant virus.
Related Links:
OyaGen, Inc.
National Institute of Allergy and Infectious Diseases
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans